TREATMENT OF PATIENTS wITH OSTEOPOROSIS IN MODERN CLINICAL PRACTICE: ADHERENCE TO THERAPY
Abstract
Aim. To assess the patients compliance to treatment of osteoporosis (OP). Materials and methods. Poll study of random sample of 1565 patients (86% women and 14% men) with OP aged 50 years and older (mean age 64 ± 7 years) from 10 cities of five federal districts of the Russian Federation with the duration of the disease a year or more. Results. Over the previous year before the survey, preparations for the treatment of OP took 96% of patients but were adherent to it only 40% of patients. Age, education, and the presence of any previous fractures had no effect on adherence, while the duration of the disease and the total duration of therapy contributed to its reduction (p <0.05). All patients who received zoledronic acid and denosumab had a 100% compliance. Among taking oral bisphosphonates (BP) and strontium ranelate (SR) adherence was higher compared to those who used only calcium supplements and vitamin D (p <0.005), there were no differences in treatment adherence to BF and SR, and compliance of women was not dependent on the dosing regimen of oral BF (p> 0.05). Less committed to oral drugs were women who took more other medications. The high cost, lack of necessary medicines in the pharmacy, the duration of therapy were the most common causes of omission or substitution treatment of OP. Conclusion. In our country, patients with OP have poor adherence to medical treatment. Reduced compliance to OP therapy is due to prolonged duration of the disease, total duration of the treatment, cost of drugs or their absence in the pharmacy, and in women was dependent on the number of drugs taken.
References
1. Лесняк О.М. Аудит состояния проблемы остеопоро-за в странах Восточной Европы и Центральной Азии 2010. Остеопороз и остеопатии 2011; 2: 3-6.
2. Weycker D., Macarios D., Edelsberg J., Oster G. Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int 2006; 17(11): 1645-52.
3. Lekkerkerker F., Kanis J.A., Alsayed N., Bouvenot G., Burlet N., Cahall D., Chines A., Delmas P., Dreiser R.L., Ethgen D., Hughes N., Kaufman J.M., Korte S., Kreutz G., Laslop A., Mitlak B., Rabenda V., Rizzoli R., Santora A., Schimmer R., Tsouderos Y., Viethel P., Reginster J.Y.; Group for the Respect of Ethics and Excellence in Science (GREES). Adherence to treatment of osteoporosis: a need for study. Osteoporos Int 2007; 18: 1311 - 1317.
4. Kothawala P., Badamgarav E., Ryu S., Miller R.M., Halbert R.J. Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo clin Proc. 2007; 82(12): 1493-501.
5. Евстигнеева Л.П., Лесняк О.М., Кузнецова Н.М., Сафонова Ю.А., Булгакова С.В., Кирпикова М.Н., Струнина М.В., Телющенко М.В., Некрасова М.Р., Несмеянова О.Б., Воробьева А.А. Образовательная программа для пациентов с остеопорозом и ее влияние на приверженность к лечению: результаты многоцентрового рандомизированного исследования. Остеопороз и остеопатии 2012; 2: 33-37.
6. Лесняк О.М., Евстигнеева Л.П., Коваль A.M., Беневоленская Л.И., Виноградова И.Б., Древаль А.В., Ершова О.Б., Иванова О.Н., Зазерская И.Е., Зоткин Е.Г., Коган И.Ю., Кочеткова Е.А., Меньшикова ю Л.В., Попов А.А., Родионова С.С., Рожинская и Л.Я., Скрипникова И.А., Черных Т.М. Приверженность российских пациентов лечению остеопороза (национальный проект «Сила в постоянстве»). Фарма-тека 2008; 3: 73-79.
7. Торопцова Н.В., Никитинская О.А., Добровольская О.В. Приверженность лечению больных остеопорозом в реальной клинической практике. Научно-практическая ревматология. 2014; 52(3): 336-341
8. Curtis J.R., Westfall A.O., Cheng H., Lyles K., Saag K.G., Delzell E. Benefit of adherence with bisphosphonates depends on age and fracture type: results from an analysis of 101,038 new bisphosphonate users. J Bone Miner Res. 2008 Sep; 23(9): 1435-41.
9. Penning-van Beest F.J., Erkens J.A., Olson M., Herings R.M. Determinants of non-compliance with bisphosphonates in women with postmenopausal osteoporosis. Curr Med Res Opin. 2008; 24(5): 1337-44.
10. Cotte F.E., Fardellone P., Mercier F., Gaudin A.F., Roux C. Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis. Osteoporos Int. 2010; 21(1): 145-55. оригинальные статьи
11. Solomon D.H., Brookhart M.A., Tsao P., Sundaresan D., Andrade S.E., Mazor K., Yood R. Predictors of very low adherence with medications for osteoporosis: towards development of a clinical prediction rule. Osteoporos Int. 2011; 22(6): 1737-43.
12. Tosteson A.N., Do T.P., Wade S.W., Anthony M.S., Downs R.W. Persistence and switching patterns among women with varied osteoporosis medication histories: 12-month results from POSSIBLE US. Osteoporos Int. 2010; 21(10): 1769-80.
13. McHorney C.A., Schousboe J.T., Cline R.R., Weiss T.W. The impact of osteoporosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates. Curr. Med. Res. Opin. 2007; 23: 3137-3152
14. Kennedy J., Teleu I., Mackay K. Unfilled prescriptions of Medicare beneficiaries: prevalence, reasons, and types of medicines prescribed. J. Manag. CarePharm. 2008; 14(6): 553-560.
15. Weiss T.W., Henderson S.C., McHorney C.A., Cramer J.A. Persistence across weekly and monthly bisphosphonates: analysis of US retail pharmacy prescription refills. Curr. Med. Res. Opin. 2007; 23(9): 2193-2203.
16. Emkey R., Koltun W., Beusterien K., Seidman L., Kivitz A., Devas V., Masanauskaite D. Patient preference for oncemonthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). Curr. Med. Res. Opin. 2005; 21(12): 1895-1903.
17. Lewiecki E.M., Babbitt A.M., Piziak V.K., Ozturk Z.E., Bone H.G._Adherence to and gastrointestinal tolerability of monthly oral and quarterly intravenous ibandronate in women with previous intolerance in oral bisphosphonates: a 12-month, open-label prospective evaluation. Clin. Ther. 2008; 30: 605-621. doi: 10.1016/j.clinthera.2008.04.009
18. Saag K., Lindsay R., Kriegman A., Beamer E., Zhou W. A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density. Bone 2007; 40: 1238-1243.doi: 10.1016/j.bone.2007.01.016
19. Kendler D.L., Bessette L., Hill C.D., Gold D.T., Horne R., Varon S.F., Borenstein J., Wang H., Man H.S., Wagman R.B., Siddhanti S., Macarios D., Bone H.G. Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass. Osteoporos. Int. 2010; 21: 837-846.
20. Audran M., Jakob F.J., Palacios S., Brandi M.L., Bröll H., Hamdy N.A., McCloskey E.V. A large prospective European cohort study of patients treated with strontium ranelate and followed up over 3 years. Rheumatol Int. 2013; 33(9): 2231-9.
21. Grant A.M., Avenell A., Campbell M.K., McDonald A.M., MacLennan G.S., McPherson G.C., Anderson F.H., Cooper C., Francis R.M., Donaldson C., Gillespie W.J., Robinson C.M., Torgerson D.J., Wallace W.A.; RECORD Trial Group. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial. Lancet 2006; 365: 1621-1628.
22. Jackson R.D., LaCroix A.Z., Gass M., Wallace R.B., Robbins J., Lewis C.E., Bassford T., Beresford S.A., Black H.R., Blanchette P., Bonds D.E., Brunner R.L., Brzyski R.G., Caan B., Cauley J.A., Chlebowski R.T., Cummings S.R., Granek I., Hays J., Heiss G., Hendrix S.L., Howard B.V., Hsia J., Hubbell F.A., Johnson K.C., Judd H., Kotchen J.M., Kuller L.H., Langer R.D., Lasser N.L., Limacher M.C., Ludlam S., Manson J.E., Margolis K.L., McGowan J., Ockene J.K., O’Sullivan M.J., Phillips L., Prentice R.L., Sarto G.E., Stefanick M.L., Van Horn L., Wactawski-Wende J., Whitlock E., Anderson G.L., Assaf A.R., Barad D.; Women’s Health Initiative Investigator s. Women’s Health Initiative Investigators. Calcium plus vitamin D supplementation and the risk of fractures. N. Engl. J. Med. 2006; 354: 669-683.
Review
For citations:
Nikitinskaya O.A., Toroptsova N.V., Feklistov A.Y., Demin N.V., Abramkin A. TREATMENT OF PATIENTS wITH OSTEOPOROSIS IN MODERN CLINICAL PRACTICE: ADHERENCE TO THERAPY. Osteoporosis and Bone Diseases. 2015;18(1):23-27. (In Russ.)
Views:
3811
Email this article 
